Proteomics in Clinical Trials and Practice
Open accessThe DOI matches its Crossref record; 66 of the 69 references it cites were found in a registry or an index.
Abstract
The study of clinical proteomics is a promising new field that has the potential to have many applications, including the identification of biomarkers and monitoring of disease, especially in the field of oncology. Expression proteomics evaluates the cellular production of proteins encoded by a particular gene and exploits the differential expression and post-translational modifications of proteins between healthy and diseased states. These biomarkers may be applied towards early diagnosis, prognosis, and prediction of response to therapy. Functional proteomics seeks to decipher protein-protein interactions and biochemical pathways involved in disease biology and targeted by newer molecular therapeutics. Advanced spectrometry technologies and new protein array formats have improved these analyses and are now being applied prospectively in clinical trials. Further advancement of proteomics technology could usher in an era of personalized molecular medicine, where diseases are diagnosed at earlier stages and where therapies are more effective because they are tailored to the protein expression of a patient's malignancy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A range of clinical samples including serum, urine, or biopsy tissue, have been studied using top-down proteomics to identify protein profiles characteristic of a certain disease generating a more reliable biomarker [155–157].”
From Top-down proteomics: challenges, innovations, and applications in basic and clinical research (2020) · cites this paper as [155]
Citations
Cites
Use of proteomic patterns in serum to identify ovarian cancer
Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07746-2 · Cited by 3,236
Self-citationMass Spectrometry and Protein Analysis
Domon, B., & Aebersold, R. (2006) · Science · doi:10.1126/science.1124619 · Cited by 2,181 · cited 1×
“within test samples such as serum (12).”
Li, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y., & Chan, D. W. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1296 · Cited by 893
Varambally, S., Yu, J., Laxman, B., Rhodes, D. R., Mehra, R., Tomlins, S. A., Shah, R. B., Chandran, U., Monzon, F. A., Becich, M. J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.001 · Cited by 800 · cited 2×
“Proteomic changes between localized and metastatic cancer that were concordant with differences in gene transcription did predict clinical outcome, indicating a potential integrative role of genomics and proteomics in prognosis (39).”
BackgroundSerum Proteomic Patterns for Detection of Prostate Cancer
Petricoin, E. F. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.20.1576 · Cited by 736 · cited 1×
“It correctly identified 95% of patients with prostate cancer and 78% of patients with benign conditions in this retrospective serum cohort (19).”
BackgroundSingle Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells
Irish, J. M., Hovland, R., Krutzik, P. O., Perez, O. D., Bruserud, Ø., Gjertsen, B. T., & Nolan, G. P. (2004) · Cell · doi:10.1016/j.cell.2004.06.028 · Cited by 684 · cited 1×
“(64) demonstrated this principle with their analysis of acute myelogenous leukemia cell samples before and after treatment with chemotherapy.”
BackgroundAdam, B.-L., Qu, Y., Davis, J. W., Ward, M. D., Clements, M. A., Cazares, L. H., Semmes, O. J., Schellhammer, P. F., Yasui, Y., Feng, Z., et al. (2002) · PubMed · Cited by 612
Proteomic patterns of tumour subsets in non-small-cell lung cancer
Yanagisawa, K., Shyr, Y., Xu, B. J., Massion, P. P., Larsen, P. H., White, B. C., Roberts, J. R., Edgerton, M., Gonzalez, A., Nadaf, S., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14068-8 · Cited by 602 · cited 1×
“(40) examined 42 lung tumors and eight normal samples using MALDI-TOF and constructed a normal and malignant lung tissue proteome model based on over 1600 protein peaks.”
MethodAutoantibody Signatures in Prostate Cancer
Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., Mehra, R., Montie, J. E., Pienta, K. J., Sanda, M. G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051931 · Cited by 582 · cited 1×
“This algorithm was then applied to a blinded set of patients and appeared to be superior to PSA screening in correctly identifying affected patients with prostate cancer (21).”
MethodProteomics: new perspectives, new biomedical opportunities
Banks, R. E., Dunn, M. J., Hochstrasser, D. F., Sanchez, J.-C., Blackstock, W., Pappin, D. J., & Selby, P. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03214-1 · Cited by 451 · cited 1×
“than 500,000 proteins comprise the human proteome, derived from 35,000 genes in the human genome (3, 4).”
Background
Research works printed but not linked: 1
- Papsidero, 1981, Prostate antigen: a marker for human prostate epithelial cells, J. Natl. Cancer Inst., 66, 37
Cited by
Challenges of Cancer Biomarker Profiling
Bensalah, K., Montorsi, F., & Shariat, S. F. (2007) · European Urology · doi:10.1016/j.eururo.2007.09.036 · Cited by 224
“There is a wide range of variations in the complexity of biomarkers going from the simplest (hair color, blood pressure, or cholesterol levels) to more complicated examples, such as mRNA profiles of tumors [6,7] and, more recently, combinations of proteins [8,9].”
BackgroundTop-down proteomics: challenges, innovations, and applications in basic and clinical research
Brown, K. A., Melby, J. A., Roberts, D. S., & Ge, Y. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1855982 · Cited by 152
Roberts, D. S., Loo, J. A., Tsybin, Y. O., Liu, X., Wu, S., Chamot-Rooke, J., Agar, J. N., Paša-Tolić, L., Smith, L. M., & Ge, Y. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00318-2 · Cited by 161
Posadas, E. M., Liel, M. S., Kwitkowski, V., Minasian, L., Godwin, A. K., Hussain, M. M., Espina, V., Wood, B. J., Steinberg, S. M., & Kohn, E. C. (2007) · Cancer · doi:10.1002/cncr.22545 · Cited by 143
“are being developed to facilitate this important endpoint.(31) The current results indicated that EGFR is”
BackgroundSelf-citationProteomics role in the search for improved diagnosis, prognosis and treatment of osteoarthritis
Ruíz‐Romero, C., & Blanco, F. J. (2009) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2009.11.012 · Cited by 116
Metadata
- Authors
- Azad, N. S., Rasool, N., Annunziata, C. M., Minasian, L., Whiteley, G., & Kohn, E. C.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Azad, Nilofer S.
- Kohn, Elise C.
- Venue
- Molecular & Cellular Proteomics
- Publisher
- Elsevier BV
- Published
- 2006-10
- Volume
- 5
- Issue
- 10
- Pages
- 1819-1829
- ISSN
- 1535-9476 (ISSN-L)
- OpenAlex
- W2126134338
- Cited by
- 85
- References
- 69
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 2 · 2017: 2 · 2016: 2 · 2015: 4 · 2014: 1 · 2013: 3 · 2012: 6
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5087 d)
- Locations
- Molecular & Cellular Proteomics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- clinical proteomics, biomarker discovery, expression proteomics, functional proteomics, protein-protein interaction, post-translational modification, early diagnosis, prognosis, treatment response prediction, personalized medicine, cancer
- MeSH terms
- Clinical Trials as Topic, Humans, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Proteomics, Microdissection, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteomics in Clinical Trials and Practice. https://app.cochat.ai/papers/10.1074/mcp.r600008-mcp200
- The paper
- Azad, N. S., Rasool, N., Annunziata, C. M., Minasian, L., Whiteley, G., & Kohn, E. C. (2006). Proteomics in Clinical Trials and Practice. Molecular & Cellular Proteomics. https://doi.org/10.1074/mcp.r600008-mcp200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.